ReviewInternational journal of hematology2002
The role of WT1 in oncogenesis: tumor suppressor or oncogene?
Review in International journal of hematology, 2002. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 61 citations in OpenAlex.
- Development and preliminary validation of plasma cell-free DNA methylation-based diagnostic prediction model for colorectal cancer detection.Journal of gastrointestinal oncology · 2026Article
- Biomarker-driven neoadjuvant immunotherapy in triple-negative breast cancer: emerging therapeutic targets FOXP3 and WT1.Frontiers in immunology · 2026Review
- WT1 gene: a potential therapeutic target for multiple cancer treatment strategies.Clinical and experimental medicine · 2025Review
- Combining a WT1 Vaccine (Galinpepimut-S) With Checkpoint Inhibition (Nivolumab) in Patients With WT1-Expressing Diffuse Pleural Mesothelioma: A Phase 1 Study.JTO clinical and research reports · 2025Article
- Correlation of Wilms' Tumor 1 (WT1) with Oxidative Stress Markers and Expression of miR-361-5p; New Aspect of WT1 in Breast Cancer.Indian journal of clinical biochemistry : IJCB · 2023Article
- Application of Bioinformatics Analysis to Identify Important Pathways and Hub Genes in Ovarian Cancer Affected by WT1.Frontiers in bioengineering and biotechnology · 2021Article
- Combinational immunotherapy based on immune checkpoints inhibitors in small cell lung cancer: is this the beginning to reverse the refractory situation?Journal of thoracic disease · 2020Review
- The role of WT1 in breast cancer: clinical implications, biological effects and molecular mechanism.International journal of biological sciences · 2020Review
- Wilms' Tumor Protein 1 and Enzymatic Oxidation of 5-Methylcytosine in Brain Tumors: Potential Perspectives.Frontiers in cell and developmental biology · 2018Review
- RNA activation technique and its applications in cancer research.American journal of cancer research · 2018Review
- Trop2 and its overexpression in cancers: regulation and clinical/therapeutic implications.Genes & cancer · 2015Review
- WT1 regulates angiogenesis in Ewing Sarcoma.Oncotarget · 2014Article
- The Trop-2 signalling network in cancer growth.Oncogene · 2013Article
- Article
- Dysregulation of gene expression in the artificial human trisomy cells of chromosome 8 associated with transformed cell phenotypes.PloS one · 2011Article
- Angiotensin-(1-7) reduces fibrosis in orthotopic breast tumors.Cancer research · 2010Article
- Article
- Studies of Wilms' Tumor (WT1) Gene Expression in Adult Acute Leukemias in Singapore.Biomarker insights · 2007Article
- Regulation of vascular endothelial growth factor, VEGF, gene promoter by the tumor suppressor, WT1.Frontiers in bioscience : a journal and virtual library · 2007Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Although originally identified as a tumor suppressor gene, WT1 is overexpressed in a variety of hematologic malignancies and solid tumors, including acute leukemia, breast cancer, malignant mesothelioma, renal cell carcinoma, and others. Overexpression of both wild-type and mutant WT1 has been reported. In some cases, this finding represents overexpression of a gene that should be expressed at lower levels, but in other cases, WT1 is expressed at high levels in a tissue type in which there is normally no expression at all. In this review, the mechanisms of altered WT1 expression are explored, including changes in promoter methylation. WT1 target genes that may be important for oncogenesis are discussed, as is the use of WT1 expression as a diagnostic tool. The prognostic implications of altered WT1 expression and the potential for immunotherapy aimed at WT1 are also discussed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.